Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CASR | P41180 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12513730 | 0.92 | CASR (0.45) | HPGDCASRLMNAALDH1A1 | |
| SCHEMBL15653639 | 0.91 | GFER (0.47) | HPGDCASRRAB9ANPC1ALDH1A1 | |
| SCHEMBL2217032 | 0.91 | GFER (0.47) | HPGDCASRRAB9ANPC1ALDH1A1 | |
| SCHEMBL2217384 | 0.82 | HPGD (0.56) | HPGDCASRRAB9ALMNANPC1 | |
| SCHEMBL3657245 | 0.82 | HPGD (0.56) | HPGDCASRRAB9ALMNANPC1 | |
| SCHEMBL14409007 | 0.80 | HPGD (0.59) | HPGDRAB9ALMNANPC1ALDH1A1 | |
| SCHEMBL15131116 | 0.78 | CASR (0.54) | CASRLMNAALDH1A1DRD2DRD3 | |
| SCHEMBL13077650 | 0.78 | CASR (0.54) | CASRLMNAALDH1A1DRD2DRD3 | |
| SCHEMBL13509996 | 0.77 | HPGD (0.53) | HPGDRAB9ALMNANPC1ALDH1A1 | |
| SCHEMBL2341650 | 0.77 | POLB (0.61) | CASRLMNADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334317-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2012-12-18 | — | — | US | claimed |
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. | 2011-07-21 | — | — | US | claimed |
| EP-2212284-B1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC (US) | 2014-04-30 | — | — | EP | disclosed |
| US-8334317-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334317-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334317-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | CASR, CALCR, RYR1 | HPGD 1840/4885CASR 1/4885RAB9A 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.